OBJECTIVE: This retrospective study attempted to identify serum biomarkers that could help to indicate treatment response in advanced nonsmall-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment. METHODS: Two-dimensional fluorescence difference gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were used to identify proteins expressed in serum samples from NSCLC patients with long (>6-month) progression-free survival (PFS) periods, following EGFR-TKI treatment. RESULTS: Serum amyloid P component (APCS), α1-antitrypsin (AAT), fibrinogen-α (FGA), keratin type I cytoskeletal 10 (KRT10) and serotransferrin (TF) expression differed between samples taken from 18 patients before treatment (baseline) and when progressive disease (PD) was observed, during treatment. Changes in AAT, KRT10 and APCS levels were validated by Western blot analysis in the sample pool; findings were further validated by Western blot analysis in a random sample of four patients. These proteins were also present in serum samples obtained from the same patients at the partial response (PR) timepoint during EGFR-TKI treatment. AAT was upregulated at PD compared with baseline, but downregulated during the PR phase. CONCLUSION: These observations suggest that AAT could be used as a serological biomarker for predicting the utility of EGFR-TKI treatment for advanced NSCLC.
OBJECTIVE: This retrospective study attempted to identify serum biomarkers that could help to indicate treatment response in advanced nonsmall-cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment. METHODS: Two-dimensional fluorescence difference gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry were used to identify proteins expressed in serum samples from NSCLCpatients with long (>6-month) progression-free survival (PFS) periods, following EGFR-TKI treatment. RESULTS: Serum amyloid P component (APCS), α1-antitrypsin (AAT), fibrinogen-α (FGA), keratin type I cytoskeletal 10 (KRT10) and serotransferrin (TF) expression differed between samples taken from 18 patients before treatment (baseline) and when progressive disease (PD) was observed, during treatment. Changes in AAT, KRT10 and APCS levels were validated by Western blot analysis in the sample pool; findings were further validated by Western blot analysis in a random sample of four patients. These proteins were also present in serum samples obtained from the same patients at the partial response (PR) timepoint during EGFR-TKI treatment. AAT was upregulated at PD compared with baseline, but downregulated during the PR phase. CONCLUSION: These observations suggest that AAT could be used as a serological biomarker for predicting the utility of EGFR-TKI treatment for advanced NSCLC.
Authors: Mila Ljujic; Sanja Mijatovic; Mirna Z Bulatovic; Marija Mojic; Danijela Maksimovic-Ivanic; Dragica Radojkovic; Aleksandra Topic Journal: Pathol Oncol Res Date: 2016-09-12 Impact factor: 3.201
Authors: Marc A Schneider; Sarah Richtmann; Anna R Gründing; Sabine Wrenger; Tobias Welte; Michael Meister; Mark Kriegsmann; Hauke Winter; Thomas Muley; Sabina Janciauskiene Journal: Int J Oncol Date: 2022-02-25 Impact factor: 5.650
Authors: Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński Journal: PLoS One Date: 2022-05-05 Impact factor: 3.752